Immunomedics Announces Encouraging Preclinical Study Data, Shares Give Up Early Morning Gains
April 18, 2016 at 13:03 PM EDT
Immunomedics, Inc. (NASDAQ: IMMU), a clinical stage biopharmaceutical company that focuses on the treatment of cancer, presented data ...